Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SLGL
SELLSol-Gel Technologies Ltd. · Healthcare · Israel · $268M · Avg Vol: $4M/d
COMPANY DESCRIPTION
Sol-Gel Technologies Ltd. is a specialty pharmaceutical company focused on developing and commercializing dermatology products by leveraging its proprietary microencapsulation technology, with a pipeline addressing conditions like acne and rosacea. Its competitive moat is built upon the Sol-Gel platform, which enhances drug delivery, stability, and reduces side effects, differentiating its topical treatments. The company benefits from strong intellectual property and a focused approach within the large and growing dermatology market.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.3M | 3.9M | 1.6M | 11.5M | 19.4M | -11.3% | 18.5M | 0.2M | 0.5M | -83.9% |
| EPS | 1.40 | -6.50 | -10.01 | -3.79 | -2.19 | — | -0.30 | — | — | — |
| Shares | 2.3M | 2.3M | 2.8M | 2.8M | 2.8M | +20.5% | 3.3M | — | — | — |
| Debt | 1.6M | 0.8M | 1.7M | 1.3M | 1.0M | -11.2% | 0.9M | — | — | — |
| Equity | 55.6M | 42.2M | 38.6M | 28.9M | 22.8M | -20.0% | — | — | — | — |
| Op CF | -7.7M | -9.5M | -17.7M | -13.9M | 0.3M | — | — | — | — | — |
| Inv CF | 19.9M | 1.7M | -9.7M | 26.7M | -8.6M | — | — | — | — | — |
| Fin CF | 0.8M | 15.0K | 21.8M | 0 | 6.0K | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SLGL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SLGL | Sol-Gel Technologies Ltd.(you) | $268M | 33 | SELL |
| MDWD | MediWound Ltd. | $183M | 8 | STRONG SELL |
| ENTX | Entera Bio Ltd. | $101M | 17 | STRONG SELL |
| DRTS | Alpha Tau Medical Ltd. | $1.1B | 26 | SELL |
| PYPD | PolyPid Ltd. | $75M | 21 | SELL |
| ENLV | Enlivex Ltd. | $71M | 12 | STRONG SELL |
| CGEN | Compugen Ltd. | $216M | 98 | STRONG BUY |
| INCR | InterCure Ltd. | $55M | 36 | HOLD |
| BWAY | BrainsWay Ltd. | $641M | 51 | HOLD |
| BVC.L | BATM Advanced Communications Ltd. | $67M | 51 | HOLD |
Peer medians: ROE 5.1% · P/E 16.5x · Gross margin 36.8%